Invitation for Public Submissions:
An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis (Draft)
Organisations and members of the public with an interest in the management of juvenile idiopathic arthritis are invited to submit their comments and suggestions on the draft guideline to help inform and contribute to its development.
Submissions should be made via this survey or via MAGICapp.
Period of Public Consultation: 19 August to 19 September 2022.
About the Guideline:
An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis seeks to present the best available, current scientific evidence to assist decision making in the management of JIA. The guideline offers recommended courses of action subject to clinical judgement and patient preferences.
An Australian Living Guideline for the Management of Juvenile Idiopathic Arthritis is produced by the Australia and New Zealand Musculoskeletal (ANZMUSC) Clinical Trials Network, the Australian Rheumatology Association (ARA) and Cochrane Musculoskeletal. This living guideline is being produced with assistance from an Arthritis Australia Health Professional Education and Training grant. This grant aims to improve care for people with arthritis. The consortium is seeking NHMRC approval of the guideline under section 14A of the National Health and Medical Research Council Act 1992.
As a living guideline, additional topics will continue to be added, new recommendations developed, and existing recommendations updated. Topics and questions identified as having highest clinical relevance to medical practitioners who treat JIA will be prioritised. Currently, the draft guideline comprises three recommendations which relate to the treatment of uveitis, the use of methotrexate in the management of JIA, and the use of glucocorticoids in the management of JIA.
Further information can be viewed at: